Ekaterina Trishkina

Suggest Changes
Learn More
BACKGROUND The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after(More)
Purpose This phase III study compared SB3, a trastuzumab (TRZ) biosimilar, with reference TRZ in patients with human epidermal growth factor receptor 2-positive early breast cancer in the neoadjuvant(More)
Clinical efficacy of combined treatment of 383 patients who had undergone conservative surgery for extremity soft-tissue sarcomas (combined treatment -188; surgery alone - 195, control) was assessed.(More)
  • 1